-
1
-
-
78649603622
-
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:10-year analysis of the ATAC trial
-
doi:10.1016/S1470-2045 10 70257-6
-
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF (2010) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer:10-year analysis of the ATAC trial. Lancet Oncol 11(12):1135-1141. doi:10.1016/S1470-2045 (10) 70257-6
-
(2010)
Lancet Oncol
, vol.11
, Issue.12
, pp. 1135-1141
-
-
Cuzick, J.1
Sestak, I.2
Baum, M.3
Buzdar, A.4
Howell, A.5
Dowsett, M.6
Forbes, J.F.7
-
2
-
-
75749092296
-
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen
-
doi:10.1200/JCO.2009.23.1274
-
Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28(3):509-518. doi:10.1200/JCO.2009.23.1274
-
(2010)
J Clin Oncol
, vol.28
, Issue.3
, pp. 509-518
-
-
Dowsett, M.1
Cuzick, J.2
Ingle, J.3
Coates, A.4
Forbes, J.5
Bliss, J.6
Buyse, M.7
Baum, M.8
Buzdar, A.9
Colleoni, M.10
Coombes, C.11
Snowdon, C.12
Gnant, M.13
Jakesz, R.14
Kaufmann, M.15
Boccardo, F.16
Godwin, J.17
Davies, C.18
Peto, R.19
-
3
-
-
25844472419
-
Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation
-
doi:10.1677/erc.1.01023
-
Martin LA, Farmer I, Johnston SR, Ali S, Dowsett M (2005) Elevated ERK1/ERK2/estrogen receptor cross-talk enhances estrogen-mediated signaling during long-term estrogen deprivation. Endocr Relat Cancer 12(Suppl 1):S75-S84. doi:10.1677/erc.1.01023
-
(2005)
Endocr Relat Cancer
, vol.12
, Issue.SUPPL. 1
-
-
Martin, L.A.1
Farmer, I.2
Johnston, S.R.3
Ali, S.4
Dowsett, M.5
-
4
-
-
0042232592
-
Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation
-
doi:10.1074/jbc. M305226200
-
Martin LA, Farmer I, Johnston SR, Ali S, Marshall C, Dowsett M (2003) Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 278(33):30458-30468. doi:10.1074/jbc. M305226200
-
(2003)
J Biol Chem
, vol.278
, Issue.33
, pp. 30458-30468
-
-
Martin, L.A.1
Farmer, I.2
Johnston, S.R.3
Ali, S.4
Marshall, C.5
Dowsett, M.6
-
5
-
-
0028853923
-
Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells
-
Masamura S, Santner SJ, Heitjan DF, Santen RJ (1995) Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 80(10):2918-2925
-
(1995)
J Clin Endocrinol Metab
, vol.80
, Issue.10
, pp. 2918-2925
-
-
Masamura, S.1
Santner, S.J.2
Heitjan, D.F.3
Santen, R.J.4
-
6
-
-
49649086490
-
Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells
-
Santen RJ, Song RX, Masamura S, Yue W, Fan P, Sogon T, Hayashi S, Nakachi K, Eguchi H (2008) Adaptation to estradiol deprivation causes up-regulation of growth factor pathways and hypersensitivity to estradiol in breast cancer cells. Adv Exp Med Biol 630:19-34
-
(2008)
Adv Exp Med Biol
, vol.630
, pp. 19-34
-
-
Santen, R.J.1
Song, R.X.2
Masamura, S.3
Yue, W.4
Fan, P.5
Sogon, T.6
Hayashi, S.7
Nakachi, K.8
Eguchi, H.9
-
7
-
-
77954974573
-
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptorpositive human breast cancer
-
doi:10.1172/JCI41680
-
Miller TW, Hennessy BT, Gonzalez-Angulo AM, Fox EM, Mills GB, Chen H, Higham C, Garcia-Echeverria C, Shyr Y, Arteaga CL (2010) Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptorpositive human breast cancer. J Clin Invest 120(7):2406-2413. doi:10.1172/JCI41680
-
(2010)
J Clin Invest
, vol.120
, Issue.7
, pp. 2406-2413
-
-
Miller, T.W.1
Hennessy, B.T.2
Gonzalez-Angulo, A.M.3
Fox, E.M.4
Mills, G.B.5
Chen, H.6
Higham, C.7
Garcia-Echeverria, C.8
Shyr, Y.9
Arteaga, C.L.10
-
8
-
-
84860390340
-
Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer
-
doi:10.1186/bcr2833
-
Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, Lin L, Ellis MJ (2011) Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer. Breast Cancer Res 13(2):R21. doi:10.1186/bcr2833
-
(2011)
Breast Cancer Res
, vol.13
, Issue.2
-
-
Sanchez, C.G.1
Ma, C.X.2
Crowder, R.J.3
Guintoli, T.4
Phommaly, C.5
Gao, F.6
Lin, L.7
Ellis, M.J.8
-
9
-
-
82055187255
-
ERadependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer
-
doi:10.1158/2159-8290.cd-11-0101
-
Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira S-M, Manning HC, Gonžlez-Angulo AM, Mills GB, Higham C, Chanthaphaychith S, Kuba MG, Miller WR, Shyr Y, Arteaga CL (2011) ERadependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov 1(4):338-351. doi:10.1158/2159-8290.cd-11- 0101
-
(2011)
Cancer Discov
, vol.1
, Issue.4
, pp. 338-351
-
-
Miller, T.W.1
Balko, J.M.2
Fox, E.M.3
Ghazoui, Z.4
Dunbier, A.5
Anderson, H.6
Dowsett, M.7
Jiang, A.8
Smith, R.A.9
Maira, S.-M.10
Manning, H.C.11
Gonžlez-Angulo, A.M.12
Mills, G.B.13
Higham, C.14
Chanthaphaychith, S.15
Kuba, M.G.16
Miller, W.R.17
Shyr, Y.18
Arteaga, C.L.19
-
10
-
-
0035992421
-
The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: Long-term studies using the intratumoral aromatase postmenopausal breast cancer model
-
Long BJ, Jelovac D, Thiantanawat A, Brodie AM (2002) The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clin Cancer Res 8(7):2378-2388
-
(2002)
Clin Cancer Res
, vol.8
, Issue.7
, pp. 2378-2388
-
-
Long, B.J.1
Jelovac, D.2
Thiantanawat, A.3
Brodie, A.M.4
-
11
-
-
79960264282
-
Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance
-
doi:10.1016/j.mce. 2010.09.005
-
Sabnis G, Brodie A (2011) Adaptive changes results in activation of alternate signaling pathways and resistance to aromatase inhibitor resistance. Mol Cell Endocrinol. doi:10.1016/j.mce. 2010.09.005
-
(2011)
Mol Cell Endocrinol.
-
-
Sabnis, G.1
Brodie, A.2
-
12
-
-
67349101669
-
The androgen metabolite 5alpha-androstane-3beta, 17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: Implications for aromatase inhibitor resistance
-
doi:10.1007/s10549-008-0080-8
-
Sikora MJ, Cordero KE, Larios JM, Johnson MD, Lippman ME, Rae JM (2009) The androgen metabolite 5alpha-androstane-3beta, 17beta-diol (3betaAdiol) induces breast cancer growth via estrogen receptor: implications for aromatase inhibitor resistance. Breast Cancer Res Treat 115(2):289-296. doi:10.1007/s10549-008-0080-8
-
(2009)
Breast Cancer Res Treat
, vol.115
, Issue.2
, pp. 289-296
-
-
Sikora, M.J.1
Cordero, K.E.2
Larios, J.M.3
Johnson, M.D.4
Lippman, M.E.5
Rae, J.M.6
-
13
-
-
67650337804
-
Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: The HOBOE trial
-
doi:10.1200/JCO.2008.18.6213
-
Rossi E, Morabito A, Di Rella F, Esposito G, Gravina A, Labonia V, Landi G, Nuzzo F, Pacilio C, De Maio E, Di Maio M, Piccirillo MC, De Feo G, D'Aiuto G, Botti G, Chiodini P, Gallo C, Perrone F, De Matteis A (2009) Endocrine effects of adjuvant letrozole compared with tamoxifen in hormone-responsive postmenopausal patients with early breast cancer: the HOBOE trial. J Clin Oncol 27(19):3192-3197. doi:10.1200/JCO.2008.18.6213
-
(2009)
J Clin Oncol
, vol.27
, Issue.19
, pp. 3192-3197
-
-
Rossi, E.1
Morabito, A.2
Di Rella, F.3
Esposito, G.4
Gravina, A.5
Labonia, V.6
Landi, G.7
Nuzzo, F.8
Pacilio, C.9
De Maio, E.10
Di Maio, M.11
Piccirillo, M.C.12
De Feo, G.13
D'Aiuto, G.14
Botti, G.15
Chiodini, P.16
Gallo, C.17
Perrone, F.18
De Matteis, A.19
-
14
-
-
82955249033
-
Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy
-
doi:10.1007/s10549-011-1611-2
-
Gallicchio L, Macdonald R, Wood B, Rushovich E, Helzlsouer KJ (2011) Androgens and musculoskeletal symptoms among breast cancer patients on aromatase inhibitor therapy. Breast Cancer Res Treat. doi:10.1007/s10549-011-1611-2
-
(2011)
Breast Cancer Res Treat.
-
-
Gallicchio, L.1
Macdonald, R.2
Wood, B.3
Rushovich, E.4
Helzlsouer, K.J.5
-
15
-
-
0141499607
-
The pharmacology of letrozole
-
Haynes BP, Dowsett M, Miller WR, Dixon JM, Bhatnagar AS (2003) The pharmacology of letrozole. J Steroid Biochem Mol Biol 87(1):35-45
-
(2003)
J Steroid Biochem Mol Biol
, vol.87
, Issue.1
, pp. 35-45
-
-
Haynes, B.P.1
Dowsett, M.2
Miller, W.R.3
Dixon, J.M.4
Bhatnagar, A.S.5
-
16
-
-
43249113162
-
Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer
-
doi:10.1200/JCO.2007.13.9279
-
Dixon JM, Renshaw L, Young O, Murray J, Macaskill EJ, McHugh M, Folkerd E, Cameron DA, A'Hern RP, Dowsett M (2008) Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 26(10):1671-1676. doi:10.1200/JCO.2007.13.9279
-
(2008)
J Clin Oncol
, vol.26
, Issue.10
, pp. 1671-1676
-
-
Dixon, J.M.1
Renshaw, L.2
Young, O.3
Murray, J.4
Macaskill, E.J.5
McHugh, M.6
Folkerd, E.7
Cameron, D.A.8
A'Hern, R.P.9
Dowsett, M.10
-
17
-
-
21644489751
-
GREB 1 is a critical regulator of hormone dependent breast cancer growth
-
doi:10.1007/s10549-005-1483-4
-
Rae JM, Johnson MD, Scheys JO, Cordero KE, Larios JM, Lippman ME (2005) GREB 1 is a critical regulator of hormone dependent breast cancer growth. Breast Cancer Res Treat 92(2):141-149. doi:10.1007/s10549-005-1483-4
-
(2005)
Breast Cancer Res Treat
, vol.92
, Issue.2
, pp. 141-149
-
-
Rae, J.M.1
Johnson, M.D.2
Scheys, J.O.3
Cordero, K.E.4
Larios, J.M.5
Lippman, M.E.6
-
18
-
-
0018940905
-
Lippman ME (1980) The effects of 17b estradiol and tamoxifen on the ZR-75-1 human breast cancer cell line in defined medium
-
Allegra JC (1965) Lippman ME (1980) The effects of 17b estradiol and tamoxifen on the ZR-75-1 human breast cancer cell line in defined medium. Eur J Cancer 16(8):1007-1015
-
(1965)
Eur J Cancer
, vol.16
, Issue.8
, pp. 1007-1015
-
-
Allegra, J.C.1
-
19
-
-
0035710746
-
Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-delta delta C (T)) method
-
doi:10.1006/meth.2001.1262
-
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2 (-delta delta C (T)) method. Methods 25(4):402-408. doi:10.1006/meth.2001.1262
-
(2001)
Methods
, vol.25
, Issue.4
, pp. 402-408
-
-
Livak, K.J.1
Schmittgen, T.D.2
-
20
-
-
79960264727
-
New and translational perspectives of oestrogen deprivation in breast cancer
-
doi:10.1016/j.mce.2010.12.034
-
Dunbier AK, Martin LA, Dowsett M (2011) New and translational perspectives of oestrogen deprivation in breast cancer. Mol Cell Endocrinol. doi:10.1016/j.mce.2010.12.034
-
(2011)
Mol Cell Endocrinol.
-
-
Dunbier, A.K.1
Martin, L.A.2
Dowsett, M.3
-
21
-
-
0035971181
-
Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: A new model for anti-estrogen resistance
-
doi:10.1074/jbc
-
Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H (2001) Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor alpha: a new model for anti-estrogen resistance. J Biol Chem 276(13):9817-9824. doi:10.1074/jbc
-
(2001)
J Biol Chem
, vol.276
, Issue.13
, pp. 9817-9824
-
-
Campbell, R.A.1
Bhat-Nakshatri, P.2
Patel, N.M.3
Constantinidou, D.4
Ali, S.5
Nakshatri, H.6
-
22
-
-
0037173738
-
Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera
-
doi:10.1038/sj.onc.1205420
-
Chen D, Washbrook E, Sarwar N, Bates GJ, Pace PE, Thirunuvakkarasu V, Taylor J, Epstein RJ, Fuller-Pace FV, Egly JM, Coombes RC, Ali S (2002) Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 21(32):4921-4931. doi:10.1038/sj.onc.1205420
-
(2002)
Oncogene
, vol.21
, Issue.32
, pp. 4921-4931
-
-
Chen, D.1
Washbrook, E.2
Sarwar, N.3
Bates, G.J.4
Pace, P.E.5
Thirunuvakkarasu, V.6
Taylor, J.7
Epstein, R.J.8
Fuller-Pace, F.V.9
Egly, J.M.10
Coombes, R.C.11
Ali, S.12
-
23
-
-
33751552134
-
Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity
-
doi:10.1210/me.2006-0068
-
Likhite VS, Stossi F, Kim K, Katzenellenbogen BS, Katzenellenbogen JA (2006) Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity. Mol Endocrinol 20(12):3120-3132. doi:10.1210/me.2006-0068
-
(2006)
Mol Endocrinol
, vol.20
, Issue.12
, pp. 3120-3132
-
-
Likhite, V.S.1
Stossi, F.2
Kim, K.3
Katzenellenbogen, B.S.4
Katzenellenbogen, J.A.5
-
24
-
-
2942592008
-
Dual kinase inhibition in the treatment of breast cancer: Initial experience with the EGFR/ErbB-2 inhibitor lapatinib
-
Burris HA III (2004) Dual kinase inhibition in the treatment of breast cancer: initial experience with the EGFR/ErbB-2 inhibitor lapatinib. Oncologist 9(Suppl 3):10-15
-
(2004)
Oncologist
, vol.9
, Issue.SUPPL. 3
, pp. 10-15
-
-
Burris III, H.A.1
-
25
-
-
33751205030
-
Lapatinib: Current status and future directions in breast cancer
-
doi:10.1634/theoncologist.11-10-1047
-
Moy B, Goss PE (2006) Lapatinib: current status and future directions in breast cancer. Oncologist 11(10):1047-1057. doi:10.1634/theoncologist.11-10-1047
-
(2006)
Oncologist
, vol.11
, Issue.10
, pp. 1047-1057
-
-
Moy, B.1
Goss, P.E.2
-
26
-
-
39149111976
-
Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer
-
doi:10.1200/JCO.2007.11.5451
-
Partridge AH, La Fountain A, Mayer E, Taylor BS, Winer E, Asnis-Alibozek A (2008) Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26(4):556-562. doi:10.1200/JCO.2007.11. 5451
-
(2008)
J Clin Oncol
, vol.26
, Issue.4
, pp. 556-562
-
-
Partridge, A.H.1
La Fountain, A.2
Mayer, E.3
Taylor, B.S.4
Winer, E.5
Asnis-Alibozek, A.6
-
27
-
-
79954575067
-
High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to Anti-IGF-IR therapy
-
doi:10.1158/1078-0432.ccr-10-1903
-
Litzenburger BC, Creighton CJ, Tsimelzon A, Chan BT, Hilsenbeck SG, Wang T, Carboni JM, Gottardis MM, Huang F, Chang JC, Lewis MT, Rimawi MF, Lee AV (2011) High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to Anti-IGF-IR therapy. Clin Cancer Res 17(8):2314-2327. doi:10.1158/1078-0432.ccr-10-1903
-
(2011)
Clin Cancer Res
, vol.17
, Issue.8
, pp. 2314-2327
-
-
Litzenburger, B.C.1
Creighton, C.J.2
Tsimelzon, A.3
Chan, B.T.4
Hilsenbeck, S.G.5
Wang, T.6
Carboni, J.M.7
Gottardis, M.M.8
Huang, F.9
Chang, J.C.10
Lewis, M.T.11
Rimawi, M.F.12
Lee, A.V.13
-
28
-
-
80155131176
-
A Kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer
-
doi:10.1158/0008-5472.can-11-1295
-
Fox EM, Miller TW, Balko JM, Kuba MG, Sánchez V, Smith RA, Liu S, González-Angulo AM, Mills GB, Ye F, Shyr Y, Manning HC, Buck E, Arteaga CL (2011) A Kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer. Cancer Res 71(21):6773-6784. doi:10.1158/0008-5472.can-11-1295
-
(2011)
Cancer Res
, vol.71
, Issue.21
, pp. 6773-6784
-
-
Fox, E.M.1
Miller, T.W.2
Balko, J.M.3
Kuba, M.G.4
Sánchez, V.5
Smith, R.A.6
Liu, S.7
González-Angulo, A.M.8
Mills, G.B.9
Ye, F.10
Shyr, Y.11
Manning, H.C.12
Buck, E.13
Arteaga, C.L.14
-
30
-
-
78649701331
-
Targeting endocrine resistance: Is there a role for mTOR inhibition?
-
Sheri A, Martin L-A, Johnston S (2010) Targeting endocrine resistance: Is there a role for mTOR inhibition? Clin Breast Cancer 10:S79-S85
-
(2010)
Clin Breast Cancer
, vol.10
-
-
Sheri, A.1
Martin, L.-A.2
Johnston, S.3
-
31
-
-
84863078767
-
Everolimus in postmenopausal hormone-receptorâ positive advanced breast cancer
-
doi:10.1056/NEJMoa1109653
-
Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN (2011) Everolimus in postmenopausal hormone-receptorâ positive advanced breast cancer. N Engl J Med 366(6):520-529. doi:10.1056/NEJMoa1109653
-
(2011)
N Engl J Med
, vol.366
, Issue.6
, pp. 520-529
-
-
Baselga, J.1
Campone, M.2
Piccart, M.3
Burris, H.A.4
Rugo, H.S.5
Sahmoud, T.6
Noguchi, S.7
Gnant, M.8
Pritchard, K.I.9
Lebrun, F.10
Beck, J.T.11
Ito, Y.12
Yardley, D.13
Deleu, I.14
Perez, A.15
Bachelot, T.16
Vittori, L.17
Xu, Z.18
Mukhopadhyay, P.19
Lebwohl, D.20
Hortobagyi, G.N.21
more..
-
32
-
-
0034876707
-
Estrogenic impurities in labware
-
doi:10.1038/nbt0901-812
-
Ishikawa T, Takano K, Yasufuku-Takano J, Fujita T, Igarashi T, Miura M, Hata K (2001) Estrogenic impurities in labware. Nat Biotechnol 19(9):812. doi:10.1038/nbt0901-812
-
(2001)
Nat Biotechnol
, vol.19
, Issue.9
, pp. 812
-
-
Ishikawa, T.1
Takano, K.2
Yasufuku-Takano, J.3
Fujita, T.4
Igarashi, T.5
Miura, M.6
Hata, K.7
-
33
-
-
38049008502
-
27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator
-
doi:10.1210/me.2007-0383
-
Du Sell CD, Umetani M, Shaul PW, Mangelsdorf DJ, McDonnell DP (2008) 27-Hydroxycholesterol is an endogenous selective estrogen receptor modulator. Mol Endocrinol 22(1):65-77. doi:10.1210/me.2007-0383
-
(2008)
Mol Endocrinol
, vol.22
, Issue.1
, pp. 65-77
-
-
Du Sell, C.D.1
Umetani, M.2
Shaul, P.W.3
Mangelsdorf, D.J.4
McDonnell, D.P.5
-
34
-
-
0024500567
-
Androstenedione and androst-5-ene-3b, 17b-diol stimulate DMBA-induced rat mammary tumors-role of aromatase
-
doi:10.1007/bf01806551
-
Dauvois S, Labrie F (1989) Androstenedione and androst-5-ene-3b, 17b-diol stimulate DMBA-induced rat mammary tumors-role of aromatase. Breast Cancer Res Treat 13(1):61-69. doi:10.1007/bf01806551
-
(1989)
Breast Cancer Res Treat
, vol.13
, Issue.1
, pp. 61-69
-
-
Dauvois, S.1
Labrie, F.2
-
35
-
-
79956106152
-
Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer
-
Stanway SJ, Palmieri C, Stanczyk FZ, Folkerd EJ, Dowsett M, Ward R, Coombes RC, Reed MJ, Purohit A (2011) Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer. Anticancer Res 31(4):1367-1372
-
(2011)
Anticancer Res
, vol.31
, Issue.4
, pp. 1367-1372
-
-
Stanway, S.J.1
Palmieri, C.2
Stanczyk, F.Z.3
Folkerd, E.J.4
Dowsett, M.5
Ward, R.6
Coombes, R.C.7
Reed, M.J.8
Purohit, A.9
-
36
-
-
0022899836
-
Intratissular androgens in benign prostatic hyperplasia and prostatic cancer
-
Voigt KD, Bartsch W (1986) Intratissular androgens in benign prostatic hyperplasia and prostatic cancer. J Steroid Biochem 25 (5 B):749-757
-
(1986)
J Steroid Biochem
, vol.25
, Issue.5 B
, pp. 749-757
-
-
Voigt, K.D.1
Bartsch, W.2
-
37
-
-
34250878367
-
Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy
-
Santen RJ, Demers L, Ohorodnik S, Settlage J, Langecker P, Blanchett D, Goss PE, Wang S (2007) Superiority of gas chromatography/tandem mass spectrometry assay (GC/MS/MS) for estradiol for monitoring of aromatase inhibitor therapy. Steroids 72(8):666-671
-
(2007)
Steroids
, vol.72
, Issue.8
, pp. 666-671
-
-
Santen, R.J.1
Demers, L.2
Ohorodnik, S.3
Settlage, J.4
Langecker, P.5
Blanchett, D.6
Goss, P.E.7
Wang, S.8
-
38
-
-
77951050920
-
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer
-
doi:10.1158/0008-5472.can-09-3024
-
Ingle JN, Buzdar AU, Schaid DJ, Goetz MP, Batzler A, Robson ME, Northfelt DW, Olson JE, Perez EA, Desta Z, Weintraub RA, Williard CV, Flockhart DA, Weinshilboum RM (2010) Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res 70(8):3278-3286. doi:10.1158/0008-5472.can-09-3024
-
(2010)
Cancer Res
, vol.70
, Issue.8
, pp. 3278-3286
-
-
Ingle, J.N.1
Buzdar, A.U.2
Schaid, D.J.3
Goetz, M.P.4
Batzler, A.5
Robson, M.E.6
Northfelt, D.W.7
Olson, J.E.8
Perez, E.A.9
Desta, Z.10
Weintraub, R.A.11
Williard, C.V.12
Flockhart, D.A.13
Weinshilboum, R.M.14
-
39
-
-
70249128382
-
Enhancing the efficacy of hormonal agents with selected targeted agents
-
doi:10.3816/CBC.2009.s.003
-
Johnston SR (2009) Enhancing the efficacy of hormonal agents with selected targeted agents. Clin Breast Cancer 9(Suppl 1):S28-S36. doi:10.3816/CBC.2009.s.003
-
(2009)
Clin Breast Cancer
, vol.9
, Issue.SUPPL. 1
-
-
Johnston, S.R.1
-
40
-
-
78049523306
-
Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer
-
doi:10.1200/JCO.2010.28.8415
-
Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martin M (2010) Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 28(30):4594-4600. doi:10.1200/JCO.2010.28.8415
-
(2010)
J Clin Oncol
, vol.28
, Issue.30
, pp. 4594-4600
-
-
Di Leo, A.1
Jerusalem, G.2
Petruzelka, L.3
Torres, R.4
Bondarenko, I.N.5
Khasanov, R.6
Verhoeven, D.7
Pedrini, J.L.8
Smirnova, I.9
Lichinitser, M.R.10
Pendergrass, K.11
Garnett, S.12
Lindemann, J.P.13
Sapunar, F.14
Martin, M.15
|